Evofem Bioscienc Financials
This page shows Evofem Bioscienc (EVFM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Evofem Bioscienc has an operating margin of 16.7%, meaning the company retains $17 of operating profit per $100 of revenue. This results in a moderate score of 59/100, indicating healthy but not exceptional operating efficiency. This is up from -39.6% the prior year.
Evofem Bioscienc's revenue grew a modest 4.2% year-over-year to $20.2M. This slow but positive growth earns a score of 40/100.
Evofem Bioscienc's current ratio of 0.18 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 0/100, which could limit financial flexibility.
While Evofem Bioscienc generated -$2.0M in operating cash flow, capex of $5K consumed most of it, leaving -$2.0M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Evofem Bioscienc scores -64.53, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.1M) relative to total liabilities ($94.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Evofem Bioscienc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Evofem Bioscienc generates $-5.09 in operating cash flow (-$2.0M OCF vs $391K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Evofem Bioscienc earns $1.4 in operating income for every $1 of interest expense ($3.4M vs $2.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Evofem Bioscienc generated $20.2M in revenue in fiscal year 2025. This represents an increase of 4.2% from the prior year.
Evofem Bioscienc's EBITDA was $3.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 155.4% from the prior year.
Evofem Bioscienc reported $391K in net income in fiscal year 2025. This represents an increase of 104.4% from the prior year.
Evofem Bioscienc earned $0.00 per diluted share (EPS) in fiscal year 2025. This represents an increase of 100.0% from the prior year.
Cash & Balance Sheet
Evofem Bioscienc generated -$2.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 48.8% from the prior year.
Evofem Bioscienc held $578K in cash against $0 in long-term debt as of fiscal year 2025.
Evofem Bioscienc had 127M shares outstanding in fiscal year 2025. This represents an increase of 11.8% from the prior year.
Margins & Returns
Evofem Bioscienc's gross margin was 77.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 3.1 percentage points from the prior year.
Evofem Bioscienc's operating margin was 16.7% in fiscal year 2025, reflecting core business profitability. This is up 56.4 percentage points from the prior year.
Evofem Bioscienc's net profit margin was 1.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 47.7 percentage points from the prior year.
Capital Allocation
Evofem Bioscienc invested $5K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 64.3% from the prior year.
EVFM Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.6M+93.1% | $5.0M+2.6% | $4.8M+471.0% | $845K-88.1% | $7.1M+58.0% | $4.5M+8.1% | $4.2M+15.5% | $3.6M |
| Cost of Revenue | $2.6M+186.4% | $905K+19.9% | $755K+106.8% | $365K-75.9% | $1.5M+74.0% | $869K+13.0% | $769K+12.4% | $684K |
| Gross Profit | $7.0M+72.2% | $4.0M-0.6% | $4.1M+747.9% | $480K-91.4% | $5.6M+54.2% | $3.6M+7.0% | $3.4M+16.2% | $2.9M |
| R&D Expenses | N/A | N/A | N/A | N/A | $649K+95.5% | $332K+23.0% | $270K-54.5% | $594K |
| SG&A Expenses | $1.1M-47.5% | $2.1M+13.3% | $1.8M-22.1% | $2.4M-30.9% | $3.4M+12.1% | $3.1M+34.6% | $2.3M-19.7% | $2.8M |
| Operating Income | $3.3M+251.7% | $951K+176.0% | -$1.3M-482.6% | $327K+132.6% | -$1.0M+58.9% | -$2.4M-75.7% | -$1.4M+51.2% | -$2.8M |
| Interest Expense | $602K+0.5% | $599K+1.9% | $588K+1.9% | $577K0.0% | $577K+3.8% | $556K+1.8% | $546K-3.2% | $564K |
| Income Tax | N/A | -$4K-157.1% | $7K | N/A | N/A | -$8K-200.0% | $8K | N/A |
| Net Income | $2.8M+277.7% | -$1.6M+12.1% | -$1.8M-286.6% | $956K+131.5% | -$3.0M-28.4% | -$2.4M-275.1% | $1.4M+128.1% | -$4.8M |
| EPS (Diluted) | N/A | $-0.01+50.0% | $-0.02 | $0.00 | N/A | $-0.02 | $0.00+100.0% | $-0.16 |
EVFM Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $20.3M+46.8% | $13.8M-4.0% | $14.4M+11.7% | $12.9M-45.9% | $23.8M-0.6% | $23.9M+180.0% | $8.6M+4.1% | $8.2M |
| Current Assets | $15.3M+93.0% | $7.9M-11.7% | $9.0M+52.7% | $5.9M-56.8% | $13.6M+58.7% | $8.6M+18.9% | $7.2M+4.2% | $6.9M |
| Cash & Equivalents | $578K-31.2% | $840K+12.3% | $748K+238.5% | $221K-70.2% | $741K+2.6% | $722K+4.3% | $692K+0.4% | $689K |
| Inventory | $1.1M-33.0% | $1.7M-11.6% | $1.9M-15.8% | $2.3M+43.5% | $1.6M+7.8% | $1.5M+38.0% | $1.1M-18.8% | $1.3M |
| Accounts Receivable | $12.5M+181.4% | $4.4M-10.1% | $4.9M+329.4% | $1.1M-88.3% | $9.8M+82.3% | $5.4M+16.8% | $4.6M+7.2% | $4.3M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $94.6M+6.5% | $88.9M+5.8% | $84.0M+1.9% | $82.5M-13.2% | $95.0M+5.5% | $90.1M+15.7% | $77.9M-1.3% | $78.9M |
| Current Liabilities | $84.8M+8.5% | $78.2M+5.8% | $73.9M+4.3% | $70.9M-11.9% | $80.4M+5.5% | $76.3M+4.2% | $73.2M-1.4% | $74.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$74.3M+1.0% | -$75.1M-7.8% | -$69.6M0.0% | -$69.6M+2.3% | -$71.3M-0.5% | -$70.9M-2.3% | -$69.3M+1.9% | -$70.7M |
| Retained Earnings | -$897.4M+0.3% | -$900.2M-0.2% | -$898.5M-0.2% | -$896.7M+0.1% | -$897.7M-0.3% | -$894.6M-0.3% | -$892.3M+0.1% | -$893.6M |
EVFM Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $31K-90.8% | $336K+111.5% | -$2.9M-621.3% | $560K+123.3% | -$2.4M-424.6% | -$459K+59.8% | -$1.1M-1027.6% | $123K |
| Capital Expenditures | $3K | $0 | N/A | N/A | $0 | $0 | $0-100.0% | $14K |
| Free Cash Flow | $28K-91.7% | $336K | N/A | N/A | -$2.4M-424.6% | -$459K+59.8% | -$1.1M-1146.8% | $109K |
| Investing Cash Flow | -$3K | $0+100.0% | -$2K+96.5% | -$57K-23.9% | -$46K+91.0% | -$509K | $0+100.0% | -$14K |
| Financing Cash Flow | -$290K-18.9% | -$244K-109.5% | $2.6M+1996.3% | -$135K-105.5% | $2.5M+147.8% | $998K | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EVFM Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.9%-8.8pp | 81.7%-2.6pp | 84.4%+27.6pp | 56.8%-21.9pp | 78.7%-1.9pp | 80.7%-0.8pp | 81.5%+0.5pp | 81.0% |
| Operating Margin | 35.0%+15.8pp | 19.2%+45.1pp | -25.9%-64.6pp | 38.7%+52.8pp | -14.1%+40.1pp | -54.3%-20.9pp | -33.4%+45.5pp | -78.9% |
| Net Margin | 29.2%+60.8pp | -31.7%+5.3pp | -37.0%-150.1pp | 113.1%+155.9pp | -42.8%+9.9pp | -52.6%-85.1pp | 32.5%+165.9pp | -133.5% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 13.8%+25.1pp | -11.4%+1.0pp | -12.4%-19.8pp | 7.4%+20.2pp | -12.8%-2.9pp | -9.9%-25.7pp | 15.8%+74.3pp | -58.5% |
| Current Ratio | 0.18+0.1 | 0.10-0.0 | 0.12+0.0 | 0.08-0.1 | 0.17+0.1 | 0.11+0.0 | 0.100.0 | 0.09 |
| Debt-to-Equity | -1.27-0.1 | -1.18+0.0 | -1.21-0.0 | -1.19+0.1 | -1.33-0.1 | -1.27-0.1 | -1.120.0 | -1.12 |
| FCF Margin | 0.3%-6.5pp | 6.8% | N/A | N/A | -33.9%-23.7pp | -10.2%+17.2pp | -27.4%-30.5pp | 3.0% |
Note: Shareholder equity is negative (-$74.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.18), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Evofem Bioscienc's annual revenue?
Evofem Bioscienc (EVFM) reported $20.2M in total revenue for fiscal year 2025. This represents a 4.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Evofem Bioscienc's revenue growing?
Evofem Bioscienc (EVFM) revenue grew by 4.2% year-over-year, from $19.4M to $20.2M in fiscal year 2025.
Is Evofem Bioscienc profitable?
Yes, Evofem Bioscienc (EVFM) reported a net income of $391K in fiscal year 2025, with a net profit margin of 1.9%.
What is Evofem Bioscienc's EBITDA?
Evofem Bioscienc (EVFM) had EBITDA of $3.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Evofem Bioscienc's gross margin?
Evofem Bioscienc (EVFM) had a gross margin of 77.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Evofem Bioscienc's operating margin?
Evofem Bioscienc (EVFM) had an operating margin of 16.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Evofem Bioscienc's net profit margin?
Evofem Bioscienc (EVFM) had a net profit margin of 1.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Evofem Bioscienc's free cash flow?
Evofem Bioscienc (EVFM) generated -$2.0M in free cash flow during fiscal year 2025. This represents a 48.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Evofem Bioscienc's operating cash flow?
Evofem Bioscienc (EVFM) generated -$2.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Evofem Bioscienc's total assets?
Evofem Bioscienc (EVFM) had $20.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Evofem Bioscienc's capital expenditures?
Evofem Bioscienc (EVFM) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Evofem Bioscienc's current ratio?
Evofem Bioscienc (EVFM) had a current ratio of 0.18 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Evofem Bioscienc's debt-to-equity ratio?
Evofem Bioscienc (EVFM) had a debt-to-equity ratio of -1.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Evofem Bioscienc's return on assets (ROA)?
Evofem Bioscienc (EVFM) had a return on assets of 1.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Evofem Bioscienc's cash runway?
Based on fiscal year 2025 data, Evofem Bioscienc (EVFM) had $578K in cash against an annual operating cash burn of $2.0M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Evofem Bioscienc's debt-to-equity ratio negative or unusual?
Evofem Bioscienc (EVFM) has negative shareholder equity of -$74.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Evofem Bioscienc's Altman Z-Score?
Evofem Bioscienc (EVFM) has an Altman Z-Score of -64.53, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Evofem Bioscienc's Piotroski F-Score?
Evofem Bioscienc (EVFM) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Evofem Bioscienc's earnings high quality?
Evofem Bioscienc (EVFM) has an earnings quality ratio of -5.09x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Evofem Bioscienc cover its interest payments?
Evofem Bioscienc (EVFM) has an interest coverage ratio of 1.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Evofem Bioscienc?
Evofem Bioscienc (EVFM) scores 25 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.